SEAGULL HEALTH
Your health,We care!
As the world’s first and only highly selective JAK1 inhibitor, golidocitinib demonstrates significant efficacy in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) with a lower risk of off-target adverse reactions.
AuthenticGuaranteeFast DeliveryPrivacy On June 24, 2024, the National Medical Products Administration (NMPA) conditionally approved the marketing of Golidocitinib Capsules for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) who have received at least one prior line of systemic therapy.
On June 24, 2024, the National Medical Products Administration (NMPA) conditionally approved the marketing of Golidocitinib Capsules (trade name: Gaor···【Read More】
Update: 06 Feb,2026Source: Haiou HealthViews: 112
Copyright 2024 @ haiouhealth.com All right reserved Seagull health | Bigbear Pharmaceutical | Lucius Pharmaceuticals | 老挝全球药房
